GpR3: Gastroparesis Registry 3
Study Details
Study Description
Brief Summary
The purpose of this study is to create a new registry of patients with gastroparesis in order to better understand the characteristics of patients with gastroparesis and follow how their condition changes over time. The data collected may improve the understanding of the condition to enable better diagnosis and treatment.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
|
Detailed Description
GpR 3 is an observational study of patients with symptoms of gastroparesis with either delayed or normal gastric emptying. Epidemiological, clinical, physiological, and patient outcome data will be collected to characterize the patients and their clinical course to better understand this disorder. The long-term goal is to help phenotype patients into pathophysiologically defined subsets. This classification will provide a foundation for translational research, facilitating the search for etiopathogenesis and enhance the ability to define and conduct large clinical trials, ultimately leading to the development of more rational and effective therapeutic approaches for gastroparesis.
The primary objectives of the Gastroparesis Registry 3 (GpR 3) are:
-
To create a new registry of patients with symptoms of gastroparesis, both patients with delayed gastric emptying and patients with similar symptoms but normal gastric emptying, for the enhanced study of symptoms, gastric motility abnormalities, patient characteristics, and degree of morbidity.
-
To follow a well-characterized cohort to further define the natural history and clinical course of patients with symptoms of gastroparesis - both symptoms and gastric emptying over time. Treatments given for their clinical care and clinical responses to treatments will be recorded.
-
To provide a reliable source for recruitment of well-characterized patients with gastroparesis for other studies including therapeutic clinical trials, pathophysiological, molecular, histopathologic, or other ancillary studies. These subsequent clinical trials or ancillary studies will be conducted under separate study protocols with separate consent processes.
Specific secondary objectives of GpR3 have been developed to allow the patients entered in
GpR3 to help advance our understanding of gastroparesis:
-
Assess several areas of gastric motility in patients with symptoms of gastroparesis (fundic accommodation, antral contractility, global gastric emptying).
-
Determine the change in gastric motility over time, in patients with gastroparesis and in patients with symptoms of gastroparesis but normal gastric emptying.
-
Evaluate the clinical symptomatic course (outcome) of patients followed in the registry.
-
Use the registry to better capture clinical treatment responses to specific treatments while patients are in the registry.
-
Characterize abdominal pain in patients with gastroparesis and gastroparesis-like syndrome by:
-
Describing the abdominal pain seen in patients with gastroparesis
-
Determining if the pain has neuropathic or nociceptive qualities
-
Determining attributes of patients with abdominal pain
-
Assessing patients in the presence of sensory gastric dysfunction
-
Objective mapping of the abdominal pain and determining central and/or peripheral attributes of the abdominal pain
-
Compare the Rome IV categories of gastric disorders (functional dyspepsia (FD), epigastric pain syndrome (EPS), postprandial distress syndrome (PDS), chronic idiopathic nausea and vomiting (CINV), rumination syndrome, cyclic vomiting syndrome, central abdominal pain syndrome) to our present classification of gastroparesis and gastroparesis-like disorder.
-
Determine the prevalence of hypermobility spectrum disorders (HSD) in patients with gastroparesis.
-
Compare the water load satiety test (WLST) to intragastric meal distribution (IMD) during scintigraphy and to symptoms of early satiety, postprandial fullness in patients with symptoms of gastroparesis.
-
Collect serum, plasma, and peripheral blood mononuclear cells (PBMC) that can be used for subsequent analysis to address specific research questions.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Diabetic Participants with a primary etiology of diabetic gastroparesis |
|
| Idiopathic Participants with a primary etiology of idiopathic gastroparesis |
|
| Post-fundoplication Participants with a primary etiology of post-Nissen fundoplication gastroparesis |
|
| Diabetic with Normal Emptying Diabetic participants with symptomatic nausea and vomiting with normal gastric emptying |
|
| Idiopathic with Normal Emptying Idiopathic participants with symptomatic nausea and vomiting with normal gastric emptying |
|
| Post-fundoplication with Normal Emptying Post-fundoplication participants with symptomatic nausea and vomiting with normal gastric emptying |
Outcome Measures
Primary Outcome Measures
- Change from baseline GSCI score at 48 weeks [Baseline to 48 weeks]
The outcome is assessed using the self-reported postprandial fullness/early satiety subscore, which is computed as the average of 4 scores for 4-items on the Gastroparesis Cardinal Symptom Index (GCSI) survey: stomach fullness, inability to finish a normal-sized meal, feeling excessively full after meals, and loss of appetite. Each item is scored from 0 (no) to 5 (very severe) symptoms in the past 2-weeks; the subscore ranges from 0 to 5. The change is computed as the subscore at 48-weeks minus the baseline subscore.
Secondary Outcome Measures
- Change from baseline in Short Form Health Survey (SF-36v2) physical health QOL component score at 48 weeks [Baseline to 48 weeks]
The outcome is assessed using the self-reported 36-item Short Form Health Survey (SF-36v2) physical health QOL component score. The score ranges from 0 (poorest) to 100 (highest) QOL. The change is computed as the score at 48-weeks minus the baseline score.
- Change from baseline in Short Form Health Survey (SF-36v2) mental health QOL component score at 48 weeks [Baseline to 48 weeks]
The outcome is assessed using the self-reported 36-item Short Form Health Survey (SF-36v2) mental health QOL component score. The score ranges from 0 (poorest) to 100 (highest) QOL. The change is computed as the score at 48-weeks minus the baseline score.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Symptoms of gastroparesis of at least 12 weeks' duration with varying degrees of nausea, vomiting, early satiety, postprandial fullness
-
An etiology of either diabetic, idiopathic, or post-fundoplication (Nissen, Dor, or Toupet) gastroparesis or gastroparesis-like disorder (symptoms of gastroparesis but normal gastric emptying)
-
Gastric emptying scintigraphy of solids using the 4-hour Egg Beaters® protocol (or equivalent generic liquid egg white meal) within the last 6 months with either:
-
Abnormal gastric emptying rate defined as an abnormal 2 hour (>60% retention) and/or 4 hour (>10% retention) result based on a 4 hour scintigraphic gastric emptying study. (This group will comprise ~75% of patients in the registry.)
-
Patients with a normal gastric emptying rate, but who have symptoms of gastroparesis. (This group will comprise ~25% of patients in the registry.)
-
Negative upper endoscopy or upper radiographic GI series within 2 years of registration
-
Age at least 18 years at initial screening visit
Exclusion Criteria:
-
Inability to comply with or complete the gastric emptying test by scintigraphy (including allergy to eggs)
-
Use of narcotic analgesics greater than three days per week
-
Presence of other conditions that could explain the patient's symptoms:
-
Pyloric or intestinal obstruction: by EGD, UGI, or Abdominal CT
-
Active inflammatory bowel disease
-
Known eosinophilic gastroenteritis or eosinophilic esophagitis
-
Primary neurological conditions that can cause nausea and vomiting such as increased intracranial pressure, space occupying or inflammatory/infectious lesions
-
Acute renal failure
-
Chronic renal failure (serum creatinine >3 mg/dL) and/or on hemodialysis or peritoneal dialysis
-
Acute liver failure
-
Advanced liver disease (Child's B or C; a Child-Pugh-Turcotte (CPT) score of ≥7)
-
Prior gastric surgery including total or subtotal (near complete) gastric resection, esophagectomy, gastrojejunostomy, gastric bypass, gastric sleeve, pyloroplasty, pyloromyotomy. Note: patients with prior Nissen, Dor, or Toupet fundoplication will be eligible for enrollment.
-
Any other condition, which in the opinion of the investigator, could explain the symptoms or interfere with study requirements
-
Inability to obtain informed consent
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | University of Louisville | Louisville | Kentucky | United States | 40202 |
| 2 | Johns Hopkins Bayview Medical Center | Baltimore | Maryland | United States | 21224 |
| 3 | Massachusetts General Hospital-Digestive Healthcare Center | Boston | Massachusetts | United States | 02114 |
| 4 | Wake Forest University Health Sciences | Winston-Salem | North Carolina | United States | 27157 |
| 5 | Temple University Hospital | Philadelphia | Pennsylvania | United States | 19140 |
| 6 | Texas Tech University Health Science Center (TTUHSC) | El Paso | Texas | United States | 79905 |
Sponsors and Collaborators
- Johns Hopkins Bloomberg School of Public Health
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- Johns Hopkins University
- Massachusetts General Hospital
- Temple University
- University of Louisville
- Wake Forest University
- Texas Tech University Health Sciences Center, El Paso
Investigators
- Study Chair: Henry Parkman, MD, Temple University Hospital
- Study Chair: Braden Kuo, MD, Massachusetts General Hospital
- Study Chair: Pankaj J Pasricha, MD, Johns Hopkins University
Study Documents (Full-Text)
None provided.More Information
Additional Information:
Publications
None provided.- 7 DK GpR3
- U01DK073983
- U01DK112193
- U01DK073975
- U01DK074035
- U01DK074007
- U01DK073974
- U24DK074008